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The granuloma is the hallmark of tuberculosis (TB), at least
from the standpoint of pathology. Accordingly, this special
issue of Seminars in Immunopathology focuses on a better
understanding of immunopathology of TB, with emphasis
on the “tuberculoma” as the lesion had once been termed. In
fact, the term tuberculoma was introduced before the designa-
tions of TB and granuloma.
Intrigued by the pathologic similarities of scrofulosis and
phthisis, Franciscus Deleböe Sylvius (1614–1672) foresaw
similarities between the swollen lymph nodes in scrofulosis
and the pulmonary lesions in phthisis, and in fact, concluded
“I hold that not infrequently phthisis has its origin from these
tubercules” [1]. In a similar line, Jo Baptist Morgagni (1682–
1771) considered similar etiology of phthisis and scrofulosis
very likely [2]. It was Franciscus Deleböe Sylvius who coined
the term “tubercle.”Rudolf Virchow (1821–1902), in his book
Cellularpathologie [3], introduced the term “granuloma” for
lesions characterized by granulation and clear separation
from healthy tissue. In his treatise, Die krankhaften
Geschwülste, Virchow considered the word granuloma appro-
priate to describe such lesions [4–6]. In his view, the
tuberculoma therefore was just one form of granuloma, which
over the years replaced the specific term tuberculoma. How-
ever, it persists in describing the disease TB. This is due to
Lukas Schönlein (1793–1864), who rightly considered the
tubercle as hallmark, and hence, appropriate root word for
the clinical description of this disease [7].
Today, we know that granulomas are primarily composed
of cells of the hematopoietic lineage, notably, mononuclear
phagocytes and lymphocytes. A more careful analysis reveals
dendritic cells and neutrophils, and both Tand B lymphocytes.
Current dogma holds that T lymphocytes and mononuclear
phagocytes are the central collaboration partners in the lesion.
Granulomas are induced whenever material cannot be degrad-
ed and eliminated in due time, be it infectious as in TB or
noninfectious, as for example, in sarcoidosis. The
tuberculoma is the site of both protection and pathology since
on the one hand it constrains tubercle bacilli and on the other
hand it affects tissue function. Obviously, this has to be seen in
context: the solid and the fibrotic granulomas primarily protect,
whereas the necrotic and even more so the liquefied lesions are
primarily detrimental.
Since the elucidation of the contagious etiology of TB by
Robert Koch (1843–1910) in 1882, the granuloma has been
intensively studied from a microbiologic and immunologic
perspective. In his original publication on the etiology of
TB, Koch described the identification of the pathogen within
granulomas and stated “all these factors together allow me to
state that the bacilli present in the tuberculous lesions do not
only accompany tuberculosis but rather cause it” [8]. Elie
Metchnikoff (1845–1916), the famous discoverer of phagocy-
tosis, identified mononuclear phagocytes as major effectors
but under certain conditions also as habitat ofMycobacterium
tuberculosis. In the following are a few highlights from his
paper: “the real phagocytes (in particular macrophages) serve
as critical defenders of the host against tubercle bacilli; …
without doubt the phagocytes are capable of engulfing live
and virulent tubercle bacilli actively; …and the giant cells
are capable of killing these parasites;…of course it is possible
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that tubercle bacilli can evade the deadly activity of giant
cells” [9].
The elucidation of the contagious nature of TB by Robert
Koch in 1882 was not only the turning point for TB research
and for the development of diagnostics, therapeutics, and vac-
cines for this disease. It was also the foundation of the concept
that infectious diseases are a distinct group of pathologies
caused by exogenous invaders. This is best reflected in the
Koch–Henle postulates defining contagious disease based on
three observations [8].
1. Existence of a livingmicroorganism in all affected tissues;
2. Isolation of the infectious agent from these tissues in clon-
al form;
3. Elicitation of disease of similar type in an experimental
animal by transfer of the infectious agent.
Robert Koch made these statements while working in Ber-
lin, where Rudolf Virchow propagated cellular pathology,
meaning that diseases exclusively arise inside the cell. Exog-
enous invaders were not considered in this concept. That is,
the tuberculoma as a structured aggregation of specific host
cells was seen as testament for the endogenous origin of TB.
Identification of M. tuberculosis as agent of TB has led to
the development of diagnostics and drugs targeting the path-
ogen. These weapons unfortunately have become blunt, and
today, efforts are increasingly focused on the host response.
These include diagnostics based on global host-gene expres-
sion profiles, so-called biomarkers [10], and host-directed
therapies reverting mycobacterial subversion and misuse of
host effector mechanisms by small molecules or by monoclo-
nal antibodies. Not the least, this is the outcome of intensified
research on immunopathology of TB ranging from basic re-
search to applied investigations.
This special volume builds on the shoulders of these giants
and provides a state-of-the-art overview of the major immu-
nopathologic mechanisms underlying TB. It goes without say-
ing that the tuberculoma comprises a major part of this
volume.
Qualls and Murray view the TB granuloma from a
metabolic standpoint [11]. Over the past few years, the role of
small molecules in immunoregulation has gained increasing
interest. In TB, small molecules relevant to disease control in
the granuloma include arginine, tryptophan, as well as reactive
oxygen and nitrogen intermediates (ROI and RNI, respective-
ly). Arginase 1 is a checkpoint enzyme since by metabolizing
L-arginine it modulates RNI production, T cell proliferation,
and tryptophan degradation. Arginase 1, in turn, is induced by
lactate. BothM. tuberculosis and immunity in TB are oxygen-
dependent, and therefore, oxygen is essential for ROI and RNI
secretion and also needed by the pathogen, which can howev-
er, survive in areas of hypoxia. Investigations into the local
metabolic network in tuberculomas will not only reveal novel
insights into the crosstalk between host and pathogen at the
site of action but also provide important information about
novel therapeutic concepts. First, the activity of several con-
ventional TB drugs is highly dependent on oxygen pressure
in the granuloma, and second, manipulation of the metabolic
balance within granulomas can be harnessed for host-directed
interventional strategies.
Although the tuberculous granuloma can only fully devel-
op under the guidance of the acquired T cell response, innate
mechanisms initiate and promote this development at the early
stage of infection. With reemerging interest in the innate im-
mune system as an instructor of acquired immunity, relevant
mechanisms have been elucidated. These include the pro- and
anti-inflammatory cytokines, chemokines, lipid mediators,
and type I interferons, which all play critical roles in granulo-
ma formation. Further development of granulomas towards
fibrosis or liquefaction again is stringently orchestrated by
soluble mediators including, in addition to cytokines and
chemokines, enzymes, notably members of the matrix
metalloprotease family and cognate cell–cell interactions,
which can be costimulatory or coinhibitory. As discussed by
Dorhoi and Kaufmann, these novel insights can offer novel
directions for host-directed therapeutics for TB, some of
which have already entered clinical application for other dis-
eases, and hence, allow repurposing for TB therapy [12].
A major theme of this volume is the role of the granuloma
in protection and pathogenesis in TB. Even though there is
still a long way to go until this complex tissue reaction is fully
deciphered, first glimmers of light offer hope for directed drug
targeting of granulomas. Kiran, Podell, Chambers, and
Basaraba describe potential checkpoints for such approaches.
It is likely that these therapies serve as adjunct to conventional
rather than stand-alone therapeutics [13]. Potential approaches
include mechanisms favoring formation of solid granulomas
over necrosis and caseation, mechanisms that improve effec-
tiveness of current chemotherapy, mechanisms that prevent
spread of M. tuberculosis, and mechanisms improving tissue
modeling and healing.
The human immunodeficiency virus (HIV) is not only the
driving force for TB but the latter is also the number one cause
of death in HIV-infected individuals. As a further complication,
immune reconstitution inflammatory syndrome (IRIS) can oc-
cur after initiation of antiretroviral therapy (ART). Although
incompletely understood, this pathology is mediated by a hy-
peractivation of the immune response after reduction of viral
load. It comprises various cytokines and lymphocyte popula-
tions. Lai, Meintjes, and Wilkinson review our current knowl-
edge of this pathologic reaction, which can provide the basis for
urgently needed immune intervention measures to overcome
adverse events of this essential treatment option of the one
million HIV coinfected people developing TB every year [14].
Given the critical role of immunity in TB, host genetics
must play a major role. Indeed, it is ironic that both Koch
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and Virchow were right. Without doubt, TB is an infectious
disease, but its underlying pathology is strongly influenced by
host cell genetics. This is best illustrated by the fact that only a
small proportion of those who become infected develop active
disease, while the majority remains healthy with latent TB
infection. Yet, inheritance of TB susceptibility is not as fre-
quently found as one would assume. This is partly due to the
fact that on the one hand diagnosis of inherited diseases is
more sophisticated and, therefore, performed mostly in indus-
trialized countries, where on the other hand risk of exposure to
M. tuberculosis is relatively low. Therefore, more information
is available on inheritance correlation with non-tuberculous
mycobacterial infections and BCGosis [generalized bacille
Calmette–Guérin (BCG) disease in areas where BCG immu-
nization is performed]. Wu and Holland [15] discuss the role
of simple and complex genetic disorders in susceptibility to
mycobacterial diseases. While monogenic defects are
most frequently seen for disseminated mycobacterial disease,
lung disease caused by non-tuberculous mycobacteria is high-
ly complex including deficiencies that affect pulmonary tissue
functions. Studies focused on BCG and non-tuberculous
mycobacteria provide extremely important information about
relevant immune mechanisms. Yet, the more specific mecha-
nisms, which exclusively control pulmonary TB as the most
prevalent form of disease, remain enigmatic.
The role of the causative agent of TB, M. tuberculosis, is
the focus of the chapter by Martin, Carey, and Fortune [16].
They describe how mycobacteria respond to the unique mi-
croenvironment they face at different sites within the granulo-
ma as well as mycobacterial impact on the fate of the granu-
loma. It is becoming increasingly clear that the type of gran-
uloma that evolves is not only a matter of the host response but
also of the pathogen, i.e., the crosstalk between both. Much
needs to be understood about these mechanisms and how they
drive caseation in one lesion and sustain the solid structure in
another lesion, in one and the same patient. Current evidence
suggests that these polarizations are not stochastic but con-
trolled, although the underlying mechanisms remain elusive.
Experimental TB of mice has been instrumental for our
understanding of basic immune mechanisms in TB. Yet, the
granuloma that develops in conventional mice does not fully
reflect the composition and variability of human granulomas.
Most importantly, the pathologic mechanisms in murine and
human lesions vary significantly. The murine lesion is consid-
ered a simpler version that develops over the course of infec-
tion but does not progress into polar forms as seen in human
TB, where a spectrum of solid, necrotic, and caseous granu-
lomas is seen. However, recent advances allow harnessing the
genetic heterogeneity of different mouse strains generated by
breeding or by genetic manipulation of mice. Kramnik and
Beamer describe such models, which now make it possible
to combine our increasing knowledge about the immune re-
sponse in mice with models that more realistically mirror the
pathologies of human lesions in TB [17]. There is no doubt
that such mouse models will not only promote better mecha-
nistic understanding of granuloma formation and maintenance
but also form the basis for a pipeline of novel host-directed
interventions.
The term mycobacterium indicates phenotypic similarities
with fungi. After all, the term mycology describes the biology
of fungi and medical mycology focuses on fungal diseases.
Although Mycobacteriacae are clearly grouped as genus of
Actinobacteriacae, lessons can be learned from fungal infec-
tions. Zelante, Pieraccini, Scaringi, Aversa and Romani de-
scribe the role of major metabolites, notably, tryptophan me-
tabolites generated through host indoleamine 2,3-dioxygenase
1 (IDO1) and its crosstalk with the aryl hydrocarbon receptor
(AhR) in fungal infections [18]. Many fungi are commensals
of the human host which have to find their niche in the com-
plex world of the microbiota. Although the fungal biome is
just being elucidated, it is obvious that it will reveal novel
insights into the tripartisan crosstalk between: bacterial and
fungal commensals, bacterial/fungal pathogens, and the host
immune system. Protective immunity to many fungal patho-
gens depends on a balanced type 1 T helper (Th1)–Th17 cell
response with a strong participation of the latter. In TB, Th1
and Th17 responses are also activated and need to be well
balanced but with a preponderance of the Th1 response. This
rather simple immunologic network of CD4 T cells already
illustrates the complexity that can be easily overlooked in
systems that only study a single pathogen, considering neither
the microbiome/mycobiome nor coinfections.
Granulomas are widespread and occur whenever infectious
or noninfectious material cannot be eliminated in due time.
Although the tuberculous granuloma is often considered the
paragon of all granuomatous lesions, it is worth learning from
other examples. Here, Kaye and Beattie describe lesions in
leishmaniasis [19]. Although these lesions are simpler in struc-
tural organization than tuberculomas, they provide significant
insights into the immune regulation of granuloma formation
and protection. This may form the basis for host-directed ther-
apy of leishmaniasis based on checkpoint regulation as has
been done so successfully in certain cancer treatments.
Meijer describes a more recent innovative model to study
pathology of TB notably in the dynamic context of granuloma
formation and maintenance [20]. This is the zebrafish model,
which has already proven its high value. The advantages are
obvious. Zebrafish are naturally infected by M. marinum, a
close relative of M. tuberculosis; embryos and larvae of
zebrafish are translucent, and, therefore allow noninvasive
evaluation of the developing granuloma. Genetic manipula-
tion of zebrafish is far easier than in the mammalian system.
Taken together, the zebrafish model provides new insights into
the pathology of TB and can be harnessed as a high-
throughput system for the evaluation of novel drugs, notably
for host-directed therapy.
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This treatise summarizes recent highlights in the area of
immunopathology of TB. Although basic mechanisms are
the major topic, this information will form the basis for novel
intervention measures beyond conventional developments.
Such measures are urgently needed to fulfill the goal of the
StopTB Partnership within the World Health Organization to
reduce morbidity (9.6 million new cases in 2014) and mortal-
ity (1.5 million deaths in 2014) of TB, by 90 and 95 %, re-
spectively, by the end of 2035 [21].
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